Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-03-15 , DOI: 10.1111/jdi.13233
Kazunori Utsunomiya ₁ , Seigo Kakiuchi ₂ , Masayuki Senda ₃ , Shoko Fujii ₂ , Yuji Kurihara ₂ , Ryoji Gunji ₂ , Ryusuke Koshida ₄ , Hiroyuki Kameda ₃ , Masahiro Tamura ₃ , Kohei Kaku ₅

Affiliation

Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes mellitus to evaluate the safety and effectiveness in routine clinical practice. The 3‐ and 12‐month interim analysis showed tofogliflozin was well‐tolerated, safe and clinically effective. Here, we report the results of the 24‐month interim analysis.

中文翻译：

托格列净在日本 2 型糖尿病患者中的安全性和有效性：一项长期上市后研究 (J-STEP/LT) 的 24 个月中期分析结果。

Tofogliflozin 是一种有效的、高选择性的钠-葡萄糖协同转运蛋白 2 抑制剂，目前用于治疗 2 型糖尿病患者。我们设计了一项针对 2 型糖尿病患者的托格列净为期 3 年的研究，以评估其在常规临床实践中的安全性和有效性。 3个月和12个月的中期分析显示托格列净耐受性良好、安全且临床有效。在此，我们报告 24 个月中期分析的结果。

更新日期：2020-03-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11